OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that Paul Romness, CEO, and ...
ELIAS Animal Health, a leading companion animal cancer therapeutics company, today announced its adoptive cell therapy, ELIAS Cancer Immunotherapy (ECI®), has received full approval from the U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback